Provincial Coverage and Availability
Where and how can I get protection from RSV for my newborn?
Talk to your healthcare provider to understand the options available to you and together make an informed shared-decision how to best protect your infant from RSV disease.
Information for the 2025-2026 RSV season will be periodically updated as it becomes available.
Note: Information on availability and access is subject to change.
The provinces and territories have rolled out their publicly funded infant RSV protection programs for the 2025-2026 RSV season, with varying eligibility. See below for what is available in your province/territory. This site may not be current and will be updated periodically as new information becomes available. Please check with your healthcare provider or local public health unit for the most up to date information.
Summary of Provincial and Territories RSV Prevention Programs in Infants 1
| BC | AB | SK | MB | ON | QC | NB | NS | PEI | NL | NT | YK | NU | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABRYSVO |  |
||||||||||||
| mAB1 |  |
|
|
|
 |
|
 |
|
|
|
1 Based on media reports. Most provinces have not yet published their eligibility criteria for 2024 – 25 RSV season. NL and PEI are planning HR programs with Nirsevimab and NS considering Nirsevimab for high-risk infants.
Source:
RSV shot will be offered widely in Ontario and Quebec, but not in Western provinces – The Globe and Mail
Ontario – Respiratory Syncytial Virus prevention programs
Alberta – RSV Eligibility Criteria 2024-2025
RSV vaccine now available for all Nunavut babies | CTV News
| ABRYSVO Maternal Program | |
| mAB1 | |
| ABRYSVO | |
| ABRYSVO | |
Alberta
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): At the time of updating this site (December 2025), according to the media and a Sanofi press release, Beyfortus is expected to be offered free of charge to eligible high-risk infants only through the Alberta Paediatric RSV Prevention Program. Publicly available information from the province at this time still references the older monoclonal antibody, Palivizumab, for high-risk infants only. 2025 / 2026 resources for health professionals are being reviewed and updated and expected to be available soon.
For more information, talk to your healthcare provider or visit MyHealth Alberta and available resources.
British Columbia
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans. Abrysvo is offered free of charge to eligible First Nations pregnant individuals (32 to 36 weeks gestation before or during RSV season) through the First Nations Health Authority.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge to eligible high-risk infants and children under 2 years old through the BC Infant RSV Immunoprophylaxis Program.
For more information, talk to your healthcare provider or visit HealthLink BC and available resources.
Manitoba
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge for all infants born during RSV season between October 1, 2025, and March 31, 2026 and for high-risk children up to 24 months old.
For more information, talk to your healthcare provider or visit the Manitoba RSV Prevention Program and available resources.
New Brunswick
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge for high-risk infants born on or after April 1, 2025, and for high-risk children up to 24 months old.
For more information, talk to your healthcare provider or visit the New Brunswick Government RSV page and available resources.
Newfoundland & Labrador
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): At the time of updating this site (December 2025), according to a Sanofi press release, Beyfortus is expected to be offered free of charge to eligible high-risk infants only. Publicly available information from the province at this time still references the older monoclonal antibody, Palivizumab, for high-risk infants only. Contact your healthcare provider or local public health office for the latest program details.
For more information, talk to your healthcare provider or visit The RSV Program at the Janeway Children’s Health and Rehabilitation Centre and available resources.
Northwest Territories
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): offered free of charge for all infants born during RSV season and for infants 0 to 3 months old at the start of RSV season.
For more information, talk to your healthcare provider or visit the NWT Health and Social Services Respiratory Syncytial Virus (RSV) page and available resources.
Nova Scotia
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge for all infants less than 8 months of age entering, or born during, their first RSV season and children less than 24 months of age at increased risk of severe RSV disease entering their first or second RSV season.
For more information, talk to your healthcare provider or visit the Nova Scotia Health website and available resources.
Nunavut
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge for all infants under 12 months old for the 2025 2026 RSV season.
For more information, talk to your healthcare provider or visit the Nunavut RSV Prevention Program page.
Ontario
Maternal RSV Vaccine (Abrysvo): Offered free of charge for pregnant people between 32 to 36 weeks of pregnancy who will deliver near the start of or during RSV season.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge for all infants up to eight months old and for high-risk children up to 24 months old.
For more information, talk to your healthcare provider or visit the Ontario Ministry of Health RSV page and available resources.
Prince Edward Island
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge for all infants born during the 2025 – 2026 RSV season. Children up to 24 months old with certain health conditions are also eligible.
For more information, talk to your healthcare provider or visit the Government of Prince Edward Island RSV Protection page.
Quebec
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge to all infants born during the 2025 – 2026 RSV season. Babies born on or after April 2 of the current year who are under eight months old and entering their first RSV season may also be eligible.
For more information, talk to your healthcare provider or visit the Quebec RSV immunization page.
Saskatchewan
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): Offered free of charge to all infants born just before or during the RSV season.
For more information, talk to your healthcare provider or visit the Saskatchewan RSV Infant Immunization Program and available resources.
Yukon
Maternal RSV Vaccine (Abrysvo): Available for purchase with a prescription from your healthcare provider. Cost may be covered by some private insurance plans.
Infant Monoclonal Antibody (Beyfortus): offered free of charge for all infants, eight months and younger in their first RSV season and for high risk children up to 24 months old.
For more information, talk to your healthcare provider or visit the Yukon Immunization Program page.
British Columbia
Northwest Territories
Executive Summary: Infant RSV Protective Options in Canada for the 2025 - 2026 RSV Season
While moving towards a universal program to protect all infants from RSV disease is recommended, not all provinces are implementing a universal program this RSV season. Depending on the province, this could be due to timing, cost effectiveness, logistics for implementation, availability of supply or other factors.
In all provinces and territories in Canada, with a prescription from your healthcare provider, RSVpreF (Abrysvo®, Pfizer), the vaccine given to pregnant people between 32 and 36 weeks gestation, is available as a choice to protect infants from birth to six months of age. In Canada the list cost is approximately $230, it is available for purchase in pharmacies with a prescription from your healthcare provider, and it is covered by most private health insurance plans.
In Ontario, RSVpreF (Abrysvo®, Pfizer) is publicly funded and available at no cost to the patient for pregnant individuals between 32 to 36 weeks gestation who will deliver near the start of or during the RSV season.
In British Columbia through the First Nations Health Authority, RSVpreF (Abrysvo®, Pfizer), is publicly funded and available at no cost to the patient for eligible First Nations pregnant individuals (32 to 36 weeks gestation before or during RSV season). No reimbursement or out-of-pocket expenses are required.
In Ontario, Quebec, Nova Scotia, Prince Edward Island, Manitoba, Saskatchewan, Nunavut, Northwest Territories and Yukon, Nirsevimab (Beyfortus™, Sanofi), the monoclonal antibody given to the baby at birth, will be provided in hospital prior to discharge for all babies born during the RSV season (and in some cases for those born close to the start of RSV season) and is offered through the provincial programs at no cost to the patient. Each province and territory has its own guidelines about eligible birth dates to meet the criteria for the free immunization for the baby. Check with your healthcare provider or public health unit to find out what’s available in your jurisdiction. Healthcare providers can contact their local health authority to obtain more information about Beyfortus eligibility and access.
In British Columbia, Alberta*, New Brunswick and Newfoundland and Labrador*, Nirsevimab (Beyfortus™, Sanofi), will be provided in hospital prior to discharge for high risk infants only born during the RSV season and is offered through the provincial programs at no cost to the patient. Each province has its own eligibility criteria to define high-risk. Check with your healthcare provider or public health unit to find out what’s available in your jurisdiction. Healthcare providers can contact their local health authority to obtain more information about Beyfortus eligibility and access. *At the time of updating this website (December 2025), according to publicly available information from the Alberta and Newfoundland and Labrador governments, their infant RSV programs still reference the older monoclonal antibody, Palivizumab, for high-risk infants only. According to a Sanofi press release, Alberta and Newfoundland and Labrador are expected to transition to Beyfortus for high risk infants only in the 2025 – 2026 RSV season.
- In some provinces, Nirsevimab (Beyfortus™, Sanofi) may also be available through primary care providers or public health offices for infants born before the RSV season. Reimbursement for Beyfortus is also available through select private health insurance providers for those with private coverage and the cost is approximately $750 to $905.
- This information is changing and will be updated periodically as new information becomes available. It may not be accurate or reflect the most current, up to date information on coverage and provincial/territorial programs. Please check with your healthcare provider, public health unit or your provincial program to confirm your options for infant RSV protection this RSV season.
* List price in Canada for Nirsevimab (BeyfortusTM, Sanofi) is $952 5 and is only available through the provincial program, it is not available for purchase in pharmacies.
